Immune checkpoint inhibitors have reshaped the prognostic of several tumor types, including
metastatic colorectal tumors with microsatellite instability (MSI). However, 90-95% of …

Simple Summary Given that most patients with MSS mCRC do not respond to immunotherapy
agents or do not have durable clinical responses, there is an unmet clinical need to obtain …

Colorectal cancer (CRC) is a heterogeneous disease representing a therapeutic challenge,
which is further complicated by the common occurrence of several molecular alterations that …

Anti-BRAF/EGFR therapy was recently approved for the treatment of metastatic BRAF
V600E colorectal cancer (mCRC BRAF-V600E ). However, a large fraction of patients do not …

We build high order efficient numerical integration methods for solving the linear differential
equation $$\dot X$$ = A(t)X based on the Magnus expansion. These methods preserve …

Time-dependent perturbation theory as a tool to compute approximate solutions of the
Schrödinger equation does not preserve unitarity. Here we present, in a simple way, how the …

Purpose: Most hyperprogression disease (HPD) definitions are based on tumor growth rate (TGR).
However, there is still no consensus on how to evaluate this phenomenon. Patients …

Background & Aims After endoscopic mucosal resection (EMR) of colorectal lesions, delayed
bleeding is the most common serious complication, but there are no guidelines for its …

Purpose: OncoBEAM™ is a circulating tumor DNA (ctDNA) test that uses the BEAMing
digital PCR technology. We clarified the association between the baseline tumor burden and …

Between 8% and 12% of patients with metastatic colorectal cancer (mCRC) harbor a BRAF-V600E
mutation in their tumors, which is associated with a poor response to standard …